Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of the gastrointestinal tract. Th e seminal discovery that these tumours express the KIT tyrosine kinase and commonly harbour oncogenic mutations in the KIT gene provided the rationale for targeted therapy with tyrosine kinase inhibitors. Th e implementation of imatinib mesylate (Glivec) revolutionized the treatment of GIST as this drug achieved three times longer overall survival comparing with the historical controls in the advanced disease.
M. Kamenova [1] reviewed comprehensively the data on pathomorphological and genetic characteristics of GIST in her contribution "Pathology of Gastrointestinal Stromal Tumours with Accent to Prognostic Criteria". Th e author described in details the pathomorphological and immunohistochemical features associated with the diagnosis of GIST. She pointed out the role of a positive staining of CD117 as it was found in more than 80% of these tumours. KIT (CD117) negative tumours usually expressed PDGFR-A mutation. Further, M. Kamenova showed the criteria for GIST classifi cation in regards to the risk of aggressive behaviour -the tumour size and site, and mitotic activity. Th e author discussed comprehensively the status of diff erent KIT-and PDGFR-A mutations and their role to the prognosis and prediction to target therapy.
Th e development of a highly specifi c and eff ective targeted therapy with imatinib mesylate represents a paradigm shift in the therapy of advanced GIST. G. Kurteva and P. Kurtev [2] reviewed the clinical data in this topic in their paper "Imatinib Mesylate (Glivec) in the Management of Gastrointestinal Stromal Tumours (GIST)". Th ey showed the results of the pivotal clinical study B222 after patients have been treated with imatinib for up to 71 months (median 63 months). Median overall survival (OS) was 58 months, which was a revolutionary step in the management of advanced GIST. Further, the authors showed the results of two phase III clinical studies, EORTC 62005 and S0033, aimed to assess the relationship of the mutational status of KIT-and PDGFR-A to the effi cacy of imatinib. Th e combined analysis of these two studies demonstrated that initiating the imatinib therapy at 800 mg daily dose in patients with KIT exon 9 mutations improved progression-free survival (PFS). Th ese results provide a rationale to individualize the imatinib dosing -400 mg daily dose in patients with exon 11 mutations and 800 mg daily dose in patients with exon 9 mutations. Another issue addressed in a phase III clinical study BRF14 was the duration of imatinib therapy in patients with advanced GIST. Th e results of this trial demonstrated that imatinib should not be discontinued irrespectively of the achieved objective response and durability of the response. Th e interruption of imatinib in patients who had achieved clinical benefi t resulted in a rapid progression of the disease. Kurteva and Kurtev discussed also the safety profi le of imatinib. Th ey pointed out that imatinib therapy was discontinued because of drug-related adverse reactions only in 4% of patients. Th e most common adverse reactions were vomiting, diarrhoea, abdominal pain, fl uid retention and others. In general, imatinib was well tolerated along the treatment for many years. At the end of their manuscript the authors presented the International Guidelines for GIST management.
Th e treatment of patients with imatinib resistant GIST is a big challenge. C. Timcheva reviewed the data of investigations on primary and secondary imatinib resistance in her paper "Second-Line Targeted Th erapy of Gastrointestinal Stromal Tumours" [3] . She pointed out that 5% of patients experienced primary resistance to imatinib and another 14% developed early resistance. Th e mechanisms of primary resistance included decreased absorption of imatinib or binding of the imatinib to the blood components. Secondary resistance developed after a median of about 2 years of treatment with imatinib. It would be a result of diff erent molecular mechanisms among which the acquisition of a new, secondary mutation in KIT or PDGFR-A was the most frequent (up to 80%). Th e resistance to imatinib dosed at 400 mg daily might be overcome by increasing the daily dose to 800 mg. Recently, a pharmacokinetic study of imatinib explored the relationship between imatinib trough plasma levels and long-term clinical outcome. Th e results of this study showed that patients with imatinib trough levels <1100 ng/ml experienced a shorter time to progression (TTP) and lower rate of clinical benefi t. Th at is why the monitoring imatinib trough plasma level may be advisable in patients with lack of expected clinical benefi t, or compliance concerns. Further, C. Timcheva reviewed the results of clinical studies on second-and thirdline treatment of advanced GIST. Th e standard treatment after failure of imatinib therapy became sunitinib (a small molecule tyrosine kinase inhibitor) based on the results of phase III study comparing sunitinib with placebo. Th e benefi t of sunitinib therapy was demonstrated in terms of TTP, progression-free survival (PFS) and objective response rate (ORR). Patients who are resistant or intolerable to both imatinib and sunitinib therapy have a poor prognosis and a few Th e risk of recurrence is high after surgery. About 40-70% of patients who underwent surgery for primary tumour develop metastases. K. Koynov reviewed in his contribution "Adjuvant Th erapy with Imatinib in GIST Patients after Radical Surgery" [4] the results from clinical studies in this topic. He pointed out the signifi cance of patient categorization into four categories according to the risk of recurrence based on tumour size and mitotic count per 50 high power fi elds. Th e results of phase II clinical study Z9000 in patients with large tumours (median tumour size of 13 cm) showed that imatinib at a dose of 400 mg daily for 1 year following radical surgery improved recurrence-free survival (RFS) and OS in comparison to historical controls. Th e following phase III study Z9001 confi rmed the benefi t of adjuvant imatinib for 1 year, especially in patients with bigger tumours. One-year RFS was 97% for imatinib group and 83% for placebo group (p = 0, 0000014). Confl ict of interest Th e author declares that there is no confl ict of interest.
